Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPHNASDAQ:BIOTNASDAQ:ETNBNASDAQ:INVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$24.43+2.3%$26.04$22.64▼$53.96$1.16B0.78473,346 shs819,839 shsBIOTBiotech Acquisition$10.15-0.8%$10.15$8.30▼$10.41$291.81M-0.12244,605 shs44,400 shsETNB89bio$7.64-1.5%$7.30$4.16▼$11.84$1.11B1.231.35 million shs1.30 million shsINVAInnoviva$18.74+0.2%$17.86$15.16▼$21.28$1.17B0.35634,335 shs453,841 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals-5.06%-2.65%-10.37%-27.26%-44.12%BIOTBiotech Acquisition0.00%0.00%0.00%0.00%0.00%ETNB89bio-9.99%+2.65%+34.32%-33.53%-19.19%INVAInnoviva-0.16%+1.03%+5.59%+2.63%+21.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPHAmphastar Pharmaceuticals4.5074 of 5 stars3.03.00.03.73.84.21.3BIOTBiotech AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AETNB89bio2.9803 of 5 stars4.51.00.00.04.00.80.6INVAInnoviva4.2141 of 5 stars3.50.00.04.23.02.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.00Hold$43.5078.06% UpsideBIOTBiotech Acquisition 0.00N/AN/AN/AETNB89bio 3.00Buy$27.25256.82% UpsideINVAInnoviva 3.00Buy$55.00193.49% UpsideCurrent Analyst Ratings BreakdownLatest BIOT, INVA, ETNB, and AMPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/30/2025ETNB89bioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/24/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/10/2025AMPHAmphastar PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/8/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/22/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/21/2025AMPHAmphastar PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $32.003/14/2025ETNB89bioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$11.003/13/2025ETNB89bioCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.003/7/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/7/2025INVAInnovivaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$55.002/28/2025ETNB89bioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $21.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$731.97M1.59$3.41 per share7.17$13.35 per share1.83BIOTBiotech AcquisitionN/AN/AN/AN/A($0.95) per shareN/AETNB89bioN/AN/AN/AN/A$5.75 per shareN/AINVAInnoviva$358.71M3.27$3.62 per share5.17$10.66 per share1.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$137.54M$3.068.147.432.1921.80%26.44%11.89%5/7/2025 (Estimated)BIOTBiotech Acquisition-$6.86MN/A0.00∞N/AN/A-42.22%3.48%N/AETNB89bio-$142.19M-$3.38N/AN/AN/AN/A-59.58%-52.21%5/8/2025 (Estimated)INVAInnoviva$179.72M$0.1927.1612.09N/A18.31%20.84%11.38%5/14/2025 (Estimated)Latest BIOT, INVA, ETNB, and AMPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025AMPHAmphastar Pharmaceuticals$0.66$0.61-$0.05$0.51$173.29 millionN/A5/7/2025Q1 2025INVAInnovivaN/A$0.25N/A-$0.74N/AN/A5/1/2025Q1 2025ETNB89bio-$0.50-$0.49+$0.01-$0.49N/AN/A3/6/2025Q4 2024ETNB89bio-$0.60-$1.02-$0.42-$1.02N/AN/A2/26/2025Q4 2024INVAInnovivaN/A$0.57N/A$0.26N/A$91.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/ABIOTBiotech AcquisitionN/AN/AN/AN/AN/AETNB89bioN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.823.432.61BIOTBiotech AcquisitionN/A0.030.03ETNB89bio0.0911.6611.66INVAInnoviva0.381.791.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%BIOTBiotech Acquisition80.01%ETNB89bioN/AINVAInnoviva99.12%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.10%BIOTBiotech Acquisition19.00%ETNB89bio2.80%INVAInnoviva2.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,62047.50 million35.05 millionOptionableBIOTBiotech Acquisition428.75 million23.29 millionNot OptionableETNB89bio40145.98 million103.15 millionOptionableINVAInnoviva10062.68 million61.54 millionOptionableBIOT, INVA, ETNB, and AMPH HeadlinesRecent News About These CompaniesInnoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company ProgressMay 7 at 4:05 PM | businesswire.comSusquehanna Fundamental Investments LLC Acquires New Stake in Innoviva, Inc. (NASDAQ:INVA)May 7 at 4:18 AM | marketbeat.comFreestone Grove Partners LP Invests $674,000 in Innoviva, Inc. (NASDAQ:INVA)May 6 at 4:56 AM | marketbeat.comInnoviva (NASDAQ:INVA) Upgraded at StockNews.comMay 2, 2025 | marketbeat.comInnoviva, Inc. (NASDAQ:INVA) Shares Acquired by Dimensional Fund Advisors LPMay 2, 2025 | marketbeat.comHsbc Holdings PLC Invests $5.44 Million in Innoviva, Inc. (NASDAQ:INVA)May 1, 2025 | marketbeat.comRep. George Whitesides Unloads Shares of Innoviva, Inc. (NASDAQ:INVA)April 28, 2025 | marketbeat.comRep. George Whitesides Sells Off Shares of Innoviva, Inc. (NASDAQ:INVA)April 28, 2025 | marketbeat.comMarshall Wace LLP Buys 178,583 Shares of Innoviva, Inc. (NASDAQ:INVA)April 26, 2025 | marketbeat.comStockNews.com Downgrades Innoviva (NASDAQ:INVA) to HoldApril 23, 2025 | marketbeat.comInvesco Ltd. Has $18.25 Million Stock Holdings in Innoviva, Inc. (NASDAQ:INVA)April 21, 2025 | marketbeat.comLSV Asset Management Has $696,000 Position in Innoviva, Inc. (NASDAQ:INVA)April 17, 2025 | marketbeat.comInnoviva (NASDAQ:INVA) Raised to Buy at StockNews.comApril 16, 2025 | marketbeat.comRussell Investments Group Ltd. Decreases Stock Position in Innoviva, Inc. (NASDAQ:INVA)April 15, 2025 | marketbeat.comNorges Bank Takes $1.48 Million Position in Innoviva, Inc. (NASDAQ:INVA)April 14, 2025 | marketbeat.comInnoviva, Inc. (NASDAQ:INVA) Shares Sold by Renaissance Technologies LLCApril 12, 2025 | marketbeat.comVanguard Group Inc. Buys 84,934 Shares of Innoviva, Inc. (NASDAQ:INVA)April 10, 2025 | marketbeat.comInnoviva, Inc. (NASDAQ:INVA) Shares Sold by ExodusPoint Capital Management LPApril 9, 2025 | marketbeat.comDynamic Technology Lab Private Ltd Makes New Investment in Innoviva, Inc. (NASDAQ:INVA)April 8, 2025 | marketbeat.comBillionaire Healthcare Investor Alex Denner’s Hedge Fund Has 75% of Its Assets in These 3 StocksMarch 17, 2025 | msn.comBillionaire Healthcare Investor Alex Denner's Hedge Fund Has 75% of Its Assets in These 3 StocksMarch 17, 2025 | 247wallst.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 Biotech Giants Gaining From U.S. Sales and Policy ShiftsBy Jeffrey Neal Johnson | May 2, 2025View 3 Biotech Giants Gaining From U.S. Sales and Policy ShiftsBIOT, INVA, ETNB, and AMPH Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$24.43 +0.56 (+2.35%) Closing price 04:00 PM EasternExtended Trading$24.43 0.00 (0.00%) As of 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Biotech Acquisition NASDAQ:BIOTBiotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.89bio NASDAQ:ETNB$7.64 -0.11 (-1.46%) Closing price 03:59 PM EasternExtended Trading$7.65 +0.01 (+0.17%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Innoviva NASDAQ:INVA$18.74 +0.03 (+0.16%) Closing price 04:00 PM EasternExtended Trading$18.74 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
